Zejing Pharmaceutical (688266.SH): Key clinical trials of ZG006 for injection are being conducted and the first subject has been enrolled.

Chinavest Financial News App reported that Zhejiang Jing Pharmaceutical (688266.SH) announced that the company has recently received feedback from the China Drug Evaluation Center (CDE) of the National Medical Products Administration regarding the application for conditional approval for the marketing qualification of the company's investigational product ZG006 for injection. Based on the safety and efficacy data of injection ZG006 at the current stage and the proposed target population, CDE has agreed to conduct a key clinical trial for injection ZG006. The company is actively progressing with the key clinical trials of injection ZG006 in the proposed indication, and has recently completed the enrollment of the first subject.